Aditxt business update with Amro Albanna, co-founder and CEO

Aditxt business update with Amro Albanna, co-founder and CEO

Aditxt — 2 videos in collection

More on this equity

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. The company’s immune mapping technologies are designed to provide a personalised immune profile. Its immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies.

In this webinar, Aditxt’s CEO, Amro Albanna, is joined by Jason Kolbert, a research analyst at Dawson James. Jason asks Amro about overall business updates and milestones and the company’s acquisition strategy.


You may also be interested in these:

Healthcare

Aditxt: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free